BMO Capital Maintains Replimune(REPL.US) With Buy Rating, Raises Target Price to $18
Replimune Group Analyst Ratings
H.C. Wainwright Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $17
J.P. Morgan Maintains Replimune(REPL.US) With Buy Rating, Cuts Target Price to $16
BMO Capital Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $14
Barclays Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $17
H.C. Wainwright Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $17
Replimune Group Analyst Ratings
Replimune Group Is Maintained at Overweight by JP Morgan
J.P. Morgan Maintains Replimune(REPL.US) With Buy Rating, Raises Target Price to $17
Jefferies Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $16
Jefferies Maintains Replimune(REPL.US) With Buy Rating, Raises Target Price to $16
Replimune Group Analyst Ratings
H.C. Wainwright Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $17
Barclays Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $17
BMO Capital Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $14
H.C. Wainwright Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $17
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Replimune Group (REPL) and Hookipa Pharma (HOOK)
Replimune Group Analyst Ratings
J.P. Morgan Maintains Replimune(REPL.US) With Buy Rating, Cuts Target Price to $14